glp-1 obesity drug study august 2025 Market Pharma Giants Bet on Next-Generation
Description
Anti-Inflammatory Effects of Zingiber Officinale in Type 2 Diabetic Patients
The endocrinology market is witnessing impressive growth it is growing at a compound annual growth rate (CAGR) of 7.82 percent
As the first approved dual agonist of the GIP and GLP-1 receptors on the market, tirzepatide is considered to be a promising drug against type 2 diabetes and obesity
The condition occurs when digestive enzymes activate and attack the pancreas, and can lead to organ damage if untreated
